NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.25 -0.34 (-1.83 %)
(As of 07/20/2018 12:43 PM ET)
Previous Close$18.07
Today's Range$17.99 - $18.85
52-Week Range$12.45 - $32.00
Volume2,780 shs
Average Volume501,003 shs
Market Capitalization$1.03 billion
P/E Ratio-5.07
Dividend YieldN/A
BetaN/A
Apellis Pharmaceuticals logoApellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APLS
CUSIPN/A
Phone502-241-4114

Debt

Debt-to-Equity Ratio0.21
Current Ratio22.37
Quick Ratio22.37

Price-To-Earnings

Trailing P/E Ratio-5.07
Forward P/E Ratio-11.27
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.96 per share
Price / Book6.17

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees39
Outstanding Shares55,940,000
Market Cap$1,026.53

Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals Inc (NASDAQ:APLS) released its earnings results on Monday, April, 30th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.11. View Apellis Pharmaceuticals' Earnings History.

What price target have analysts set for APLS?

6 brokerages have issued 12 month price objectives for Apellis Pharmaceuticals' stock. Their predictions range from $23.00 to $52.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $35.40 in the next twelve months. This suggests a possible upside of 94.0% from the stock's current price. View Analyst Ratings for Apellis Pharmaceuticals.

What is the consensus analysts' recommendation for Apellis Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Apellis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (7/2/2018)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month price target of $52/share on the company’s R&D day hosted on 6/26. Apellis reviewed details for its two Phase 3 programs with APL-2 in geographic atrophy (GA) and paroxysmal nocturnal hemoglobinuria (PNH), presented initial results from its Phase 2 study in autoimmune hemolytic anemia (AIHA), and provided an update on its Phase 2 PNH study. The company also reported early enrollment of the first patient for the Phase 3 PNH trial. Based on the totality of clinical data supporting APL-2 in GA and PNH, we believe the drug is well-positioned to succeed for both indications, which appear to have blockbuster potential." (6/27/2018)

Are investors shorting Apellis Pharmaceuticals?

Apellis Pharmaceuticals saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 3,216,049 shares, an increase of 112.4% from the June 15th total of 1,514,172 shares. Based on an average daily volume of 827,292 shares, the short-interest ratio is currently 3.9 days. Currently, 10.5% of the shares of the stock are short sold. View Apellis Pharmaceuticals' Current Options Chain.

Who are some of Apellis Pharmaceuticals' key competitors?

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the folowing people:
  • Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 46)
  • Dr. Pascal Deschatelets, Co-Founder & COO (Age 48)
  • Mr. Timothy E. Sullivan, CFO & Treasurer (Age 47)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder & Sr. VP of Clinical Devel. (Age 44)
  • Mr. David O. Watson, Gen. Counsel & VP of Corp. Devel. (Age 45)

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

Has Apellis Pharmaceuticals been receiving favorable news coverage?

Media stories about APLS stock have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Apellis Pharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. They also gave media stories about the company an impact score of 45.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $18.25.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $1.03 billion. The company earns $-51,000,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Apellis Pharmaceuticals employs 39 workers across the globe.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]


MarketBeat Community Rating for Apellis Pharmaceuticals (NASDAQ APLS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.